All In Biotech

Drug Trial Radar · NCT06793215

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Nov 30, 2028

Study completion Oct 31, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

Conditions

  • Non-Small Cell Lung Cancer
  • KRAS G12C Lung Cancer

Interventions

  • DivarasibDrug

    Divarasib will be administered orally QD

  • PembrolizumabDrug

    Pembrolizumab will be administered via IV infusion Q3W

  • PemetrexedDrug

    Pemetrexed will be administered via IV infusion Q3W

  • CarboplatinDrug

    Carboplatin will be administered via IV infusion Q3W

  • CisplatinDrug

    Cisplatin will be administered via IV infusion Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 5 years
  2. Overall Survival (OS)Time frame: Up to approximately 5 years

Locations

299 sites in 28 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology

    Anchorage, Alaska · Recruiting

  • City of Hope - Phoenix

    Goodyear, Arizona · Recruiting

  • Community Cancer Institute (CCI)

    Clovis, California · Recruiting

  • Marin Cancer Care Inc

    Greenbrae, California · Recruiting

  • UCI Health-CIACC

    Irvine, California · Recruiting

  • UCLA Oncology Center

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital

    Newport Beach, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Palo Alto Medical Foundation Research Center

    Palo Alto, California · Recruiting

  • Sutter Institute for Medical Research

    Roseville, California · Recruiting

  • California Pacific Medical Center

    San Francisco, California · Recruiting

  • UC Health Oncology Research

    Colorado Springs, Colorado · Recruiting

  • Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System

    Fort Collins, Colorado · Recruiting

  • Grand Valley Oncology

    Grand Junction, Colorado · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Florida Cancer Specialists - SOUTH - SCRI - PPDS

    Fort Myers, Florida · Recruiting

  • University of Florida Health at Shands

    Gainesville, Florida · Recruiting

  • BioResearch Partner

    Hialeah, Florida · Recruiting

  • Memorial Healthcare System - Memorial Regional Hospital

    Hollywood, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Advent Health Orlando

    Orlando, Florida · Recruiting

  • Ascension Sacred Heart

    Pensacola, Florida · Recruiting

  • Florida Cancer Specialists - NORTH - SCRI - PPDS

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - EAST - SCRI - PPDS

    West Palm Beach, Florida · Recruiting

  • Piedmont Cancer Institute, PC

    Atlanta, Georgia · Recruiting

  • City of Hope® Atlanta

    Newnan, Georgia · Recruiting

  • Summit Cancer Care PC

    Savannah, Georgia · Recruiting

  • St. Luke's Cancer Institute

    Boise, Idaho · Recruiting

  • Affiliated Oncologists, LLC

    Chicago Ridge, Illinois · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Withdrawn

  • City of Hope® Cancer Center Chicago

    Zion, Illinois · Recruiting

  • Mission Cancer + Blood - IMMC

    Des Moines, Iowa · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • Saint Agnes Hospital - Baltimore - Hunt - PPDS

    Baltimore, Maryland · Recruiting

  • Walter Reed National Military Medical Center

    Bethesda, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts · Recruiting

  • Profound Research, LLC

    Farmington Hills, Michigan · Recruiting

  • Metro-Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota · Recruiting

  • University of Mississippi Medical Center

    Jackson, Mississippi · Recruiting

Showing 40 of 299 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.